Abstract
Protein arginine methylation is a widespread eukaryotic posttranslational modification that
occurs with as much frequency as ubiquitinylation. Yet, how the nine different human protein arginine
methyltransferases (PRMTs) recognize their respective protein targets is not well understood. This
review summarizes the progress that has been made over the last decade or more to resolve this significant
biochemical question. A multipronged approach involving structural biology, substrate profiling,
bioorthogonal chemistry and proteomics is discussed.
Keywords:
PRMT, arginine methylation, substrate specificity, PRMT molecular recognition, arginine methylome, target recognition.
Graphical Abstract
[38]
Duhovny, D.; Nussinov, R.; Wolfson, H.J. Efficient Unbound Docking of Rigid Molecules., 2002.
[39]
Schneidman-Duhovny, D.; Inbar, Y.; Nussinov, R.; Wolfson, H.J. PatchDock and SymmDock: servers for rigid and symmetric docking., 2005.
[43]
Mavrakis, K.J.; McDonald, E.R., III; Schlabach, M.R.; Billy, E.; Hoffman, G.R.; deWeck, A.; Ruddy, D.A.; Venkatesan, K.; Yu, J.; McAllister, G.; Stump, M.; deBeaumont, R.; Ho, S.; Yue, Y.; Liu, Y.; Yan-Neale, Y.; Yang, G.; Lin, F.; Yin, H.; Gao, H.; Kipp, D.R.; Zhao, S.; McNamara, J.T.; Sprague, E.R.; Zheng, B.; Lin, Y.; Cho, Y.S.; Gu, J.; Crawford, K.; Ciccone, D.; Vitari, A.C.; Lai, A.; Capka, V.; Hurov, K.; Porter, J.A.; Tallarico, J.; Mickanin, C.; Lees, E.; Pagliarini, R.; Keen, N.; Schmelzle, T.; Hofmann, F.; Stegmeier, F.; Sellers, W.R. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
Science, 2016,
351(6278), 1208-1213.
[
http://dx.doi.org/10.1126/science.aad5944] [PMID:
26912361]
[46]
Fedoriw, A.; Rajapurkar, S.R.; O’Brien, S.; Gerhart, S.V.; Mitchell, L.H.; Adams, N.D.; Rioux, N.; Lingaraj, T.; Ribich, S.A.; Pappalardi, M.B.; Shah, N.; Laraio, J.; Liu, Y.; Butticello, M.; Carpenter, C.L.; Creasy, C.; Korenchuk, S.; McCabe, M.T.; McHugh, C.F.; Nagarajan, R.; Wagner, C.; Zappacosta, F.; Annan, R.; Concha, N.O.; Thomas, R.A.; Hart, T.K.; Smith, J.J.; Copeland, R.A.; Moyer, M.P.; Campbell, J.; Stickland, K.; Mills, J.; Jacques-O’Hagan, S.; Allain, C.; Johnston, D.; Raimondi, A.; Porter Scott, M.; Waters, N.; Swinger, K.; Boriack-Sjodin, A.; Riera, T.; Shapiro, G.; Chesworth, R.; Prinjha, R.K.; Kruger, R.G.; Barbash, O.; Mohammad, H.P. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Cancer Cell, 2019,
36(1), 100-114.e25.
[
http://dx.doi.org/10.1016/j.ccell.2019.05.014] [PMID:
31257072]
[51]
Baldwin, R.M.; Morettin, A.; Côté, J. Role of PRMTs in cancer: Could minor isoforms be leaving a mark? World J. Biol. Chem., 2014, 5(2), 115-129.